Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Fischer, Roman ^a   Maier, Olaf ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; CHEMICAL CONTAMINATION; OXIDATIVE STRESS; PATHOLOGY; TISSUE; TISSUE REGENERATION;

CENTRAL NERVOUS SYSTEMS; FEEDFORWARD LOOPS; MASTER REGULATORS; MITOCHONDRIAL DYSFUNCTION; NEURODEGENERATION; PARKINSON'S DISEASE; REACTIVE OXYGEN AND NITROGEN SPECIES; TUMOR NECROSIS FACTORS;

NEURODEGENERATIVE DISEASES;

REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; REACTIVE NITROGEN SPECIES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ASTROCYTE; CELL ACTIVATION; CHRONIC INFLAMMATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; REVIEW; TISSUE REGENERATION; DEGENERATIVE DISEASE; METABOLISM; MITOCHONDRION; PATHOLOGY;

HUMANS; INFLAMMATION; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925337188     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/610813     Document Type: Review

References (206)

1. F. A. C. Azevedo, L. R. B. Carvalho, L. T. Grinberg et al., "Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain," Journal of Comparative Neurology, vol. 513, no. 5, pp. 532-541, 2009.
2. S. Amor, F. Puentes, D. Baker, and P. van der Valk, "Inflammation in neurodegenerative diseases," Immunology, vol. 129, no. 2, pp. 154-169, 2010.
3. V.W. Yong, "Inflammation in neurological disorders: a help or a hindrance?" The Neuroscientist, vol. 16, no. 4, pp. 408-420, 2010.
4. V. H. Perry, C. Cunningham, and C. Holmes, "Systemic infections and inflammation affect chronic neurodegeneration," Nature Reviews Immunology, vol. 7, no. 2, pp. 161-167, 2007.
5. C. Holmes, C. Cunningham, E. Zotova et al., "Systemic inflammation and disease progression in Alzheimer disease.," Neurology, vol. 73, no. 10, pp. 768-774, 2009.
6. C. Holmes and J. Butchart, "Systemic inflammation and Alzheimer's disease," Biochemical Society Transactions, vol. 39, no. 4, pp. 898-901, 2011.
7. K. Biber, T. Owens, and E. Boddeke, "What is microglia neurotoxicity (not)?" Glia, vol. 62, no. 6, pp. 841-854, 2014.
8. A. Nimmerjahn, F. Kirchhoff, and F. Helmchen, "Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo," Science, vol. 308, no. 5726, pp. 1314-1318, 2005.
9. J. Emerit, M. Edeas, and F. Bricaire, "Neurodegenerative diseases and oxidative stress," Biomedicine and Pharmacotherapy, vol. 58, no. 1, pp. 39-46, 2004.
10. H.-L. Hsieh and C.-M. Yang, "Role of redox signaling in neuroinflammation and neurodegenerative diseases," BioMed Research International, vol. 2013, Article ID 484613, 18 pages, 2013.
11. M. Schieber and N. S. Chandel, "ROS function in redox signaling and oxidative stress," Current Biology, vol. 24, no. 10, pp. R453-R462, 2014.
12. F. Zipp and O. Aktas, "The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases," Trends in Neurosciences, vol. 29, no. 9, pp. 518-527, 2006.
13. I. Figiel, "Pro-inflammatory cytokine TNF-α as a neuroprotective agent in the brain," Acta Neurobiologiae Experimentalis, vol. 68, no. 4, pp. 526-534, 2008.
14. M. K. McCoy and M. G. Tansey, "TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease," Journal of Neuroinflammation, vol. 5, article 45, 2008.
15. Y. Huang and L. Mucke, "Alzheimermechanisms and therapeutic strategies," Cell, vol. 148, no. 6, pp. 1204-1222, 2012.
16. D. Sulzer and D. J. Surmeier, "Neuronal vulnerability, pathogenesis, and Parkinson's disease," Movement Disorders, vol. 28, no. 1, pp. 41-50, 2013.
17. V. Dias, E. Junn, and M. M. Mouradian, "The role of oxidative stress in parkinson's disease," Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461-491, 2013.
18. H. Lassmann and J. van Horssen, "Themolecular basis of neurodegeneration in multiple sclerosis," FEBS Letters, vol. 585, no. 23, pp. 3715-3723, 2011.
19. R. Yamasaki, H. Lu, O. Butovsky et al., "Differential roles of microglia and monocytes in the inflamed central nervous system," The Journal of Experimental Medicine, vol. 211, no. 8, pp. 1533-1549, 2014.
20. C. W. Olanow, "A radical hypothesis for neurodegeneration," Trends in Neurosciences, vol. 16, no. 11, pp. 439-444, 1993.
21. M. di Filippo, D. Chiasserini, A. Tozzi, B. Picconi, and P. Calabresi, "Mitochondria and the link between neuroinflammation and neurodegeneration," Journal of Alzheimer's Disease, vol. 20, supplement 2, pp. S369-S379, 2010.
22. M. E. Witte, J. J. G. Geurts, H. E. de Vries, P. van der Valk, and J. van Horssen, "Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?" Mitochondrion, vol. 10, no. 5, pp. 411-418, 2010.
23. H. Lassmann, "Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease," Journal of Neural Transmission, vol. 118, no. 5, pp. 747-752, 2011.
24. P. J. Urrutia, N. P. Mena, and M. T. Núñez, "The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders," Frontiers in Pharmacology, vol. 5, article 38, 2014.
25. J. J. Haddad, "Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology," Cytokines, Cellular and Molecular Therapy, vol. 7, no. 1, pp. 1-14, 2002.
26. J. Van Horssen, M. E. Witte, G. Schreibelt, and H. E. de Vries, "Radical changes inmultiple sclerosis pathogenesis," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1812, no. 2, pp. 141-150, 2011.
27. M. P. Murphy, "How mitochondria produce reactive oxygen species," Biochemical Journal, vol. 417, no. 1, pp. 1-13, 2009.
28. 2), superoxide dismutases, and related matters," The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18515-18517, 1997.
29. M. Marí, A. Morales, A. Colell, C. García-Ruiz, N. Kaplowitz, and J. C. Fernández-Checa, "Mitochondrial glutathione: features, regulation and role in disease," Biochimica et Biophysica Acta-General Subjects, vol. 1830, no. 5, pp. 3317-3328, 2013.
30. S. J. Cooney, S. L. Bermudez-Sabogal, and K. R. Byrnes, "Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury," Journal of Neuroinflammation, vol. 10, article 155, 2013.
31. R. P. Brandes, N. Weissmann, and K. Schröder, "Nox family NADPH oxidases: molecular mechanisms of activation," Free Radical Biology and Medicine, vol. 76, pp. 208-226, 2014.
32. H.-M. Gao, H. Zhou, and J.-S. Hong, "NADPH oxidases: novel therapeutic targets for neurodegenerative diseases," Trends in Pharmacological Sciences, vol. 33, no. 6, pp. 295-303, 2012.
33. V. A. M. Vincent, F. J. H. Tilders, and A.-M. van Dam, "Production, regulation and role of nitric oxide in glial cells," Mediators of Inflammation, vol. 7, no. 4, pp. 239-255, 1998.
34. H.-Y. Yun, V. L. Dawson, and T. M. Dawson, "Neurobiology of nitric oxide," Critical Reviews in Neurobiology, vol. 10, no. 3-4, pp. 291-316, 1996.
35. A. Federico, E. Cardaioli, P. Da Pozzo, P. Formichi, G.N. Gallus, and E. Radi, "Mitochondria, oxidative stress and neurodegeneration," Journal of the Neurological Sciences, vol. 322, no. 1-2, pp. 254-262, 2012.
36. B. Bandy and A. J. Davison, "Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?" Free Radical Biology and Medicine, vol. 8, no. 6, pp. 523-539, 1990.
37. L. Morató, E. Bertini, D. Verrigni et al., "Mitochondrial dysfunction in central nervous systemwhite matter disorders," Glia, vol. 62, no. 11, pp. 1878-1884, 2014.
38. K. J. A. Davies, "Degradation of oxidized proteins by the 20s proteasome," Biochimie, vol. 83, no. 3-4, pp. 301-310, 2001.
39. M. C. Bennett, J. F. Bishop, Y. Leng, P. B. Chock, T. N. Chase, and M.M. Mouradian, "Degradation of α-synuclein by proteasome," The Journal of Biological Chemistry, vol. 274, no. 48, pp. 33855-33858, 1999.
40. L. Dupuis, "Mitochondrial quality control in neurodegenerative diseases," Biochimie, vol. 100, no. 1, pp. 177-183, 2014.
41. T. Kuwana and D. D. Newmeyer, "Bcl-2-family proteins and the role of mitochondria in apoptosis," Current Opinion in Cell Biology, vol. 15, no. 6, pp. 691-699, 2003.
42. G. Mariño, F. Madeo, and G. Kroemer, "Autophagy for tissue homeostasis and neuroprotection," Current Opinion in Cell Biology, vol. 23, no. 2, pp. 198-206, 2011.
43. P. Mecocci, U. MacGarvey, A. E. Kaufman et al., "Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain," Annals of Neurology, vol. 34, no. 4, pp. 609-616, 1993.
44. T. J. Montine, M. D. Neely, J. F. Quinn et al., "Lipid peroxidation in aging brain and Alzheimer's disease," Free Radical Biology and Medicine, vol. 33, no. 5, pp. 620-626, 2002.
45. V. M. Hubbard, R. Valdor, F. Macian, and A. M. Cuervo, "Selective autophagy in the maintenance of cellular homeostasis in aging organisms," Biogerontology, vol. 13, no. 1, pp. 21-35, 2012.
46. H. Neumann, M. R. Kotter, and R. J. M. Franklin, "Debris clearance by microglia: an essential link between degeneration and regeneration," Brain, vol. 132, no. 2, pp. 288-295, 2009.
47. S. M. de la Monte and J. R. Wands, "Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease," Journal of Alzheimer's Disease, vol. 9, no. 2, pp. 167-181, 2006.
48. M. A. Smith, P. L. R. Harris, L. M. Sayre, and G. Perry, "Iron accumulation in Alzheimer disease is a source of redoxgenerated free radicals," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 18, pp. 9866-9868, 1997.
49. A. Nunomura, G. Perry, G. Aliev et al., "Oxidative damage is the earliest event in Alzheimer disease," Journal of Neuropathology and Experimental Neurology, vol. 60, no. 8, pp. 759-767, 2001.
50. L. Devi, B. M. Prabhu, D. F. Galati, N. G. Avadhani, and H. K. Anandatheerthavarada, "Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction," The Journal of Neuroscience, vol. 26, no. 35, pp. 9057-9068, 2006.
51. A. Eckert, K. L. Schulz, V. Rhein, and J. Götz, "Convergence of amyloid-β and tau pathologies on mitochondria in vivo," Molecular Neurobiology, vol. 41, no. 2-3, pp. 107-114, 2010.
52. E. Tamagno, M. Parola, P. Bardini et al., "β-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways," Journal of Neurochemistry, vol. 92, no. 3, pp. 628-636, 2005.
53. M.A. Lovell, S. Xiong, C. Xie, P. Davies, and W. R. Markesbery, "Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3," Journal of Alzheimer's Disease, vol. 6, no. 6, pp. 659-671, 2004.
54. M. T. Lin and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases," Nature, vol. 443, no. 7113, pp. 787-795, 2006.
55. P. B. Shelat, M. Chalimoniuk, J.-H. Wang et al., "Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons," Journal of Neurochemistry, vol. 106, no. 1, pp. 45-55, 2008.
56. R.W. Mahley, K. H. Weisgraber, and Y. Huang, "Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 15, pp. 5644-5651, 2006.
57. T. G. Hastings, "The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease," Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 469-472, 2009.
58. J. Lotharius and P. Brundin, "Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein," Nature Reviews Neuroscience, vol. 3, no. 12, pp. 932-942, 2002.
59. E. Grünblatt, S. Mandel, and M. B. H. Youdim, "Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP," Annals of the New York Academy of Sciences, vol. 899, pp. 262-273, 2000.
60. R. S. Burns, C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz, and I. J. Kopin, "A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine," Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 14, pp. 4546-4550, 1983.
61. A. Bender, K. J. Krishnan, C. M. Morris et al., "High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease," Nature Genetics, vol. 38, no. 5, pp. 515-517, 2006.
62. Y. Kraytsberg, E. Kudryavtseva, A. C. McKee, C. Geula, N. W. Kowall, and K. Khrapko, "Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons," Nature Genetics, vol. 38, no. 5, pp. 518-520, 2006.
63. J. Zhu and C. T. Chu, "Mitochondrial dysfunction in Parkinson's disease," Journal of Alzheimer's Disease, vol. 20, supplement 2, pp. S325-S334, 2010.
64. S. J. Chinta, M. J. Kumar, M. Hsu et al., "Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration," The Journal of Neuroscience, vol. 27, no. 51, pp. 13997-14006, 2007.
65. H. L. Martin and P. Teismann, "Glutathione-a review on its role and significance in Parkinson's disease," The FASEB Journal, vol. 23, no. 10, pp. 3263-3272, 2009.
66. M. R. Cookson, "Parkinsonism due to mutations in PINK1, Parkin, and DJ-1 and oxidative stress and mitochondrial pathways," Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 9, Article ID a009415, 2012.
67. M.W. Dodson and M. Guo, "Pink1, parkin, DJ-1 andmitochondrial dysfunction in Parkinson's disease," Current Opinion in Neurobiology, vol. 17, no. 3, pp. 331-337, 2007.
68. N. Ostrerova-Golts, L. Petrucelli, J. Hardy, J. M. Lee, M. Farer, and B. Wolozin, "The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity," Journal of Neuroscience, vol. 20, no. 16, pp. 6048-6054, 2000.
69. L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anandatheerthavarada, "Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain," The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089-9100, 2008.
70. M. Orth, S. J. Tabrizi, C. Tomlinsonet al., "G209Amutant alphasynuclein expression specifically enhances dopamine induced oxidative damage," Neurochemistry International, vol. 45, no. 5, pp. 669-676, 2004.
71. E. Junn and M. M. Mouradian, "Human α-synuclein overexpression increases intracellular reactive oxygen species levels and susceptibility to dopamine," Neuroscience Letters, vol. 320, no. 3, pp. 146-150, 2002.
72. E. Paxinou, Q. Chen, M. Weisse et al., "Induction of α- synuclein aggregation by intracellular nitrative insult," Journal of Neuroscience, vol. 21, no. 20, pp. 8053-8061, 2001.
73. T.-B. Ahn, S. Y. Kim, J. Y. Kim et al., "α-Synuclein gene duplication is present in sporadic Parkinson disease," Neurology, vol. 70, no. 1, pp. 43-49, 2008.
74. M. Bsibsi, R. Ravid, D. Gveric, and J. M. van Noort, "Broad expression of Toll-like receptors in the human central nervous system," Journal of Neuropathology and Experimental Neurology, vol. 61, no. 11, pp. 1013-1021, 2002.
75. J. M. van Noort and M. Bsibsi, "Toll-like receptors in the CNS: implications for neurodegeneration and repair," Progress in Brain Research, vol. 175, pp. 139-148, 2009.
76. J. K. Mallajosyula, D. Kaur, S. J. Chinta et al., "MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology," PLoS ONE, vol. 3, no. 2, Article ID e1616, 2008.
77. S.-H. Chen, E. A. Oyarzabal, Y.-F. Sung et al., "Microglial regulation of immunological and neuroprotective functions of astroglia," Glia, vol. 63, no. 1, pp. 118-131, 2015.
78. R. A. Asher, D. A. Morgenstern, L.D. F. Moon, and J.W. Fawcett, "Chondroitin sulphate proteoglycans: inhibitory components of the glial scar," Progress in Brain Research, vol. 132, pp. 611-619, 2001.
79. M. V. Sofroniew, "Molecular dissection of reactive astrogliosis and glial scar formation," Trends in Neurosciences, vol. 32, no. 12, pp. 638-647, 2009.
80. H. Akiyama, S. Barger, S. Barnum et al., "Inflammation and Alzheimers disease," Neurobiology of Aging, vol. 21, no. 3, pp. 383-421, 2000.
81. R. Niranjan, "The Role of inflammatory and oxidative stress mechanisms in the pathogenesis of parkinson's disease: focus on astrocytes," Molecular Neurobiology, vol. 49, no. 1, pp. 28-38, 2014.
82. L. Qian, P. M. Flood, and J.-S. Hong, "Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy," Journal of Neural Transmission, vol. 117, no. 8, pp. 971-979, 2010.
83. C. Kim, D.-H. Ho, J.-E. Suk et al., "Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia," Nature Communications, vol. 4, article 1562, 2013.
84. S. Liu, Y. Liu, W. Hao et al., "TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation," Journal of Immunology, vol. 188, no. 3, pp. 1098-1107, 2012.
85. J. H. Hayward and S. J. Lee, "A decade of research on TLR2 discovering its pivotal role in glial activation and neuroinflammation in neurodegenerative diseases," Experimental Neurobiology, vol. 23, no. 2, pp. 138-147, 2014.
86. M. Bsibsi, C. Persoon-Deen, R. W. H. Verwer, S. Meeuwsen, R. Ravid, and J. M. Van Noort, "Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators," Glia, vol. 53, no. 7, pp. 688-695, 2006.
87. J. Li, O. Baud, T. Vartanian, J. J. Volpe, and P. A. Rosenberg, "Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 28, pp. 9936-9941, 2005.
88. C. Szabó, H. Ischiropoulos, and R. Radi, "Peroxynitrite: biochemistry, pathophysiology and development of therapeutics," Nature Reviews Drug Discovery, vol. 6, no. 8, pp. 662-680, 2007.
89. R. N. Saha and K. Pahan, "Regulation of inducible nitric oxide synthase gene in glial cells," Antioxidants and Redox Signaling, vol. 8, no. 5-6, pp. 929-947, 2006.
90. G. C. Brown, "Mechanisms of inflammatory neurodegeneration: INOS and NADPH oxidase," Biochemical Society Transactions, vol. 35, no. 5, pp. 1119-1121, 2007.
91. A. Conti, M. Miscusi, S. Cardali et al., "Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation," Brain Research Reviews, vol. 54, no. 1, pp. 205-218, 2007.
92. J. van Horssen, G. Schreibelt, J. Drexhage et al., "Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression," Free Radical Biology and Medicine, vol. 45, no. 12, pp. 1729-1737, 2008.
93. R. K. B. Pearce, A. Owen, S. Daniel, P. Jenner, and C. D. Marsden, "Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease," Journal of Neural Transmission, vol. 104, no. 6-7, pp. 661-677, 1997.
94. C. D. Smith, J. M. Carney, P. E. Starke-Reed et al., "Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 23, pp. 10540-10543, 1991.
95. L. Park, P. Zhou, R. Pitstick et al., "Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1347-1352, 2008.
96. B. Qin, L. Cartier, M. Dubois-Dauphin, B. Li, L. Serrander, and K.-H. Krause, "A key role for the microglial NADPH oxidase in APP-dependent killing of neurons," Neurobiology of Aging, vol. 27, no. 11, pp. 1577-1587, 2006.
97. J. Rodriguez-Pallares, J. A. Parga, A. Muñoz, P. Rey, M. J. Guerra, and J. L. Labandeira-Garcia, "Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons," Journal of Neurochemistry, vol. 103, no. 1, pp. 145-156, 2007.
98. L. Broom, L. Marinova-Mutafchieva, M. Sadeghian, J. B. Davis, A. D. Medhurst, and D. T. Dexter, "Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease," Free Radical Biology and Medicine, vol. 50, no. 5, pp. 633-640, 2011.
99. E. Croisier, L. B. Moran, D. T. Dexter, R. K. B. Pearce, and M. B. Graeber, "Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition," Journal of Neuroinflammation, vol. 2, article 14, 2005.
100. A. Wilkaniec, J. B. Strosznajder, and A. Adamczyk, "Toxicity of extracellular secreted alpha-synuclein: its role in nitrosative stress and neurodegeneration," Neurochemistry International, vol. 62, no. 5, pp. 776-783, 2013.
101. W. Zhang, T. Wang, Z. Pei et al., "Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease," The FASEB Journal, vol. 19, no. 6, pp. 533-542, 2005.
102. H.-M. Gao, F. Zhang, H. Zhou, W. Kam, B. Wilson, and J.- S. Hong, "Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease," Environmental Health Perspectives, vol. 119, no. 6, pp. 807-814, 2011.
103. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, "Free radicals and antioxidants in normal physiological functions and human disease," The International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44-84, 2007.
104. A. Matsuzawa and H. Ichijo, "Stress-responsive protein kinases in redox-regulated apoptosis signaling," Antioxidants and Redox Signaling, vol. 7, no. 3-4, pp. 472-481, 2005.
105. M. S. Hayden and S. Ghosh, "Shared principles in NF-kappaB signaling," Cell, vol. 132, no. 3, pp. 344-362, 2008.
106. Q. Li and I. M. Verma, "NF-κB regulation in the immune system," Nature Reviews Immunology, vol. 2, no. 10, pp. 725-734, 2002.
107. M. J. Morgan and Z.-G. Liu, "Crosstalk of reactive oxygen species and NF-κB signaling," Cell Research, vol. 21, no. 1, pp. 103-115, 2011.
108. S. Akira and K. Takeda, "Toll-like receptor signalling," Nature Reviews Immunology, vol. 4, no. 7, pp. 499-511, 2004.
109. H. Wajant, K. Pfizenmaier, and P. Scheurich, "Tumor necrosis factor signaling," Cell Death & Differentiation, vol. 10, no. 1, pp. 45-65, 2003.
110. G. Gloire, S. Legrand-Poels, and J. Piette, "NF-κB activation by reactive oxygen species: fifteen years later," Biochemical Pharmacology, vol. 72, no. 11, pp. 1493-1505, 2006.
111. P. J. Barnes and M. Karin, "Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases," The New England Journal of Medicine, vol. 336, no. 15, pp. 1066-1071, 1997.
112. Y. Deng, X. Ren, L. Yang, Y. Lin, and X. Wu, "AJNK-dependent pathway is required for TNFalpha induced apoptosis," Cell, vol. 115, no. 1, pp. 61-70, 2003.
113. S. Zhuang, J. T. Demirs, and I. E. Kochevar, "p38 mitogenactivated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide," The Journal of Biological Chemistry, vol. 275, no. 34, pp. 25939-25948, 2000.
114. C. Ploia, X. Antoniou, A. Sclip et al., "JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models," Journal of Alzheimer's Disease, vol. 26, no. 2, pp. 315-329, 2011.
115. A. Sclip, X. Antoniou, A. Colombo et al., "c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model," The Journal of Biological Chemistry, vol. 286, no. 51, pp. 43871-43880, 2011.
116. A. Sclip, A. Tozzi, A. Abaza et al., "c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo," Cell Death and Disease, vol. 5, no. 1, Article ID e1019, 2014.
117. X. Antoniou and T. Borsello, "The JNK signalling transduction pathway in the brain," Frontiers in Bioscience, vol. 1, no. 4, pp. 2110-2120, 2012.
118. J. A. Smith, A. Das, S. K. Ray, and N. L. Banik, "Role of proinflammatory cytokines released from microglia in neurodegenerative diseases," Brain Research Bulletin, vol. 87, no. 1, pp. 10-20, 2012.
119. F. M. Hofman, D. R. Hinton, K. Johnson, and J. E. Merrill, "Tumor necrosis factor identified in multiple sclerosis brain," The Journal of Experimental Medicine, vol. 170, no. 2, pp. 607-612, 1989.
120. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, "Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients," Neuroscience Letters, vol. 165, no. 1-2, pp. 208-210, 1994.
121. D.W. Dickson, "The pathogenesis of senile plaques," Journal of Neuropathology and Experimental Neurology, vol. 56, no. 4, pp. 321-339, 1997.
122. M. Grell, E. Douni, H. Wajant et al., "The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor," Cell, vol. 83, no. 5, pp. 793-802, 1995.
123. D. Aderka, "The potential biological and clinical significance of the soluble tumor necrosis factor receptors," Cytokine and Growth Factor Reviews, vol. 7, no. 3, pp. 231-240, 1996.
124. J. van Horssen, S. Singh, S. van der Pol et al., "Clusters of activated microglia in normal-appearingwhitematter showsigns of innate immune activation," Journal of Neuroinflammation, vol. 9, article 156, 2012.
125. H. Walczak, "TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer," Immunological Reviews, vol. 244, no. 1, pp. 9-28, 2011.
126. B. Kaltschmidt, P. A. Baeuerle, and C. Kaltschmidt, "Potential involvement of the transcription factor NF-κB in neurological disorders," Molecular Aspects of Medicine, vol. 14, no. 3, pp. 171-190, 1993.
127. T. Borsello and G. Forloni, "JNK signalling: a possible target to prevent neurodegeneration," Current Pharmaceutical Design, vol. 13, no. 18, pp. 1875-1886, 2007.
128. A. Paul, S. Wilson, C.M. Belhamet al., "Stress-activated protein kinases: activation, regulation and function," Cellular Signalling, vol. 9, no. 6, pp. 403-410, 1997.
129. O. Micheau and J. Tschopp, "Induction of TNF receptor Imediated apoptosis via two sequential signaling complexes," Cell, vol. 114, no. 2, pp. 181-190, 2003.
130. W. Schneider-Brachert, V. Tchikov, J. Neumeyer et al., "Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles," Immunity, vol. 21, no. 3, pp. 415-428, 2004.
131. H. Wajant and P. Scheurich, "TNFR1-induced activation of the classical NF-κBpathway," FEBS Journal, vol. 278, no. 6, pp. 862-876, 2011.
132. J. J. Kim, S. B. Lee, J. K. Park, and Y. D. Yoo, "TNF-α- induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-XL," Cell Death and Differentiation, vol. 17, no. 9, pp. 1420-1434, 2010.
133. Y. Shoji, Y. Uedono, H. Ishikura, N. Takeyama, and T. Tanaka, "DNA damage induced by tumour necrosis factor-α in L929 cells is mediated by mitochondrial oxygen radical formation," Immunology, vol. 84, no. 4, pp. 543-548, 1995.
134. T. V. Berghe, A. Linkermann, S. Jouan-Lanhouet, H. Walczak, and P. Vandenabeele, "Regulated necrosis: the expanding network of non-apoptotic cell death pathways," Nature Reviews Molecular Cell Biology, vol. 15, no. 2, pp. 135-147, 2014.
135. Z. Cai, S. Jitkaew, J. Zhao et al., "Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis," Nature Cell Biology, vol. 16, no. 1, pp. 55-65, 2014.
136. X. Chen, W. Li, J. Ren et al., "Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death," Cell Research, vol. 24, no. 1, pp. 105-121, 2014.
137. M. Rothe, S. C. Wong, W. J. Henzel, and D. V. Goeddel, "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor," Cell, vol. 78, no. 4, pp. 681-692, 1994.
138. L. Cabal-Hierro, M. Rodríguez, N. Artime et al., "TRAFmediated modulation of NF-kB AND JNK Activation by TNFR2," Cellular Signalling, vol. 26, no. 12, pp. 2658-2666, 2014.
139. P. J.W. Naudé, J. A. Den Boer, P. G. M. Luiten, and U. L. M. Eisel, "Tumor necrosis factor receptor cross-talk," The FEBS Journal, vol. 278, no. 6, pp. 888-898, 2011.
140. H. Rauert, A. Wicovsky, N. Müller et al., "Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2)," The Journal of Biological Chemistry, vol. 285, no. 10, pp. 7394-7404, 2010.
141. R. Fischer, O. Maier, M. Naumer, A. Krippner-Heidenreich, P. Scheurich, and K. Pfizenmaier, "Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway," Cellular Signalling, vol. 23, no. 1, pp. 161-170, 2011.
142. L. Marchetti, M. Klein, K. Schlett, K. Pfizenmaier, and U. L. M. Eisel, "Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by Nmethyl-D-aspartate receptor activation: Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappaB pathway," The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32869-32881, 2004.
143. A. M. Dolga, I. M. Nijholt, A. Ostroveanu, Q. T. Bosch, P.G.M. Luiten, and U. L. M. Eisel, "Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways," Journal of Alzheimer's Disease, vol. 13, no. 2, pp. 111-122, 2008.
144. R. Fischer, O. Maier, M. Siegemund, H. Wajant, P. Scheurich, and K. Pfizenmaier, "A TNF receptor 2 selective agonist rescues human neurons fromoxidative stress-induced cell death," PLoS ONE, vol. 6, no. 11, Article ID e27621, 2011.
145. M. Inoue, H. Kamada, Y. Abe et al., "Aminopeptidase P3 (APP3), a novelmember of the TNF/TNFR2 signaling complex, induces phosphorylation of JNK," Journal of Cell Science, vol. 128, no. 4, pp. 656-669, 2015.
146. B. B. Aggarwal, "Signalling pathways of the TNF superfamily: a double-edged sword," Nature Reviews Immunology, vol. 3, no. 9, pp. 745-756, 2003.
147. M. S. Dobbie, R. D. Hurst, N. J. Klein, and R. A. H. Surtees, "Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-α in an in vitro model of the blood-brain barrier," Brain Research, vol. 830, no. 2, pp. 330-336, 1999.
148. K. Wosik, K. Biernacki, M.-P. Khouzam, and A. Prat, "Death receptor expression and function at the human blood brain barrier," Journal of the Neurological Sciences, vol. 259, no. 1-2, pp. 53-60, 2007.
149. B. Engelhardt and L. Kappos, "Natalizumab: targeting α4-integrins in multiple sclerosis," Neurodegenerative Diseases, vol. 5, no. 1, pp. 16-22, 2007.
150. N. Schwab, T. Schneider-Hohendorf, and H. Wiendl, "Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis," International Immunology, vol. 27, no. 1, pp. 47-53, 2015.
151. R. E. Kontermann, P. Scheurich, and K. Pfizenmaier, "Antagonists of TNF action: clinical experience and newdevelopments," Expert Opinion on Drug Discovery, vol. 4, no. 3, pp. 279-292, 2009.
152. K. Pfizenmaier and D. E. Szymkowski, "Workshop summary: introduction to rational design of new means for therapeutic modulation of function of the TNF family," Advances in Experimental Medicine and Biology, vol. 691, pp. 487-491, 2011.
153. M. C. Hernández-Romero, M. J. Delgado-Cortés, M. Sarmiento et al., "Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system," Neuro Toxicology, vol. 33, no. 3, pp. 347-360, 2012.
154. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, "TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study," Neurology, vol. 53, no. 3, pp. 457-465, 1999.
155. C. McGuire, R. Beyaert, and G. van Loo, "Death receptor signalling in central nervous systeminflammation and demyelination," Trends in Neurosciences, vol. 34, no. 12, pp. 619-628, 2011.
156. P.M. Carvey, E.-Y. Chen, J.W. Lipton, C.W. Tong, Q. A. Chang, and Z. D. Ling, "Intra-parenchymal injection of tumor necrosis factor-α and interleukin 1-β produces dopamine neuron loss in the rat," Journal of Neural Transmission, vol. 112, no. 5, pp. 601-612, 2005.
157. L. Probert, K. Akassoglou, M. Pasparakis, G. Kontogeorgos, and G. Kollias, "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 24, pp. 11294-11298, 1995.
158. K. Sriram, J. M. Matheson, S. A. Benkovic, D. B. Miller, M. I. Luster, and J. P. O'Callaghan, "Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α1," The FASEB Journal, vol. 20, no. 6, pp. 670-682, 2006.
159. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen, "TNFalpha modulation for treatment of Alzheimer's disease: a 6-month pilot study," MedGenMed Medscape General Medicine, vol. 8, no. 2, article 25, 2006.
160. S. R. Ruuls, R. M. Hoek, V. N. Ngo et al., "Membranebound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation," Immunity, vol. 15, no. 4, pp. 533-543, 2001.
161. L. Alexopoulou, K. Kranidioti, S. Xanthoulea et al., "Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity," European Journal of Immunology, vol. 36, no. 10, pp. 2768-2780, 2006.
162. A. C. Bulua, A. Simon, R. Maddipati et al., "Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS)," The Journal of Experimental Medicine, vol. 208, no. 3, pp. 519-533, 2011.
163. R. Krüger, C. Hardt, F. Tschentscher et al., "Genetic analysis of immunomodulating factors in sporadic Parkinson's disease," Journal of Neural Transmission, vol. 107, no. 5, pp. 553-562, 2000.
164. A. P. Gregory, C. A. Dendrou, K. E. Attfield et al., "TNFreceptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis," Nature, vol. 488, no. 7412, pp. 508-511, 2012.
165. V. Fontaine, S. Mohand-Said, N. Hanoteau, C. Fuchs, K. Pfizenmaier, and U. Eisel, "Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2," The Journal of Neuroscience, vol. 22, no. 7, p. RC216, 2002.
166. A. Dellarole, P. Morton, R. Brambilla et al., "Neuropathic paininduced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling," Brain, Behavior, and Immunity, vol. 41, pp. 65-81, 2014.
167. H. P. Eugster, K. Frei, R. Bachmann, H. Bluethmann, H. Lassmann, and A. Fontana, "Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1," European Journal of Immunology, vol. 29, no. 2, pp. 626-632, 1999.
168. G. C. Suvannavejh, H.-O. Lee, J. Padilla, M. C. Dal Canto, T. A. Barrett, and S.D. Miller, "Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)- induced experimental autoimmune encephalomyelitis," Cellular Immunology, vol. 205, no. 1, pp. 24-33, 2000.
169. S. K. Williams, O. Maier, R. Fischer et al., "Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis," PLoS ONE, vol. 9, no. 2, Article ID e90117, 2014.
170. R. Brambilla, J. J. Ashbaugh, R. Magliozzi et al., "Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination," Brain, vol. 134, no. 9, pp. 2736-2754, 2011.
171. E. Taoufik, V. Tseveleki, S. Y. Chu et al., "Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB," Brain, vol. 134, no. 9, pp. 2722-2735, 2011.
172. M. K. McCoy, T. N. Martinez, K. A. Ruhn et al., "Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease," Journal of Neuroscience, vol. 26, no. 37, pp. 9365-9375, 2006.
173. M. K. McCoy, K. A. Ruhn, T. N. Martinez, F. E. McAlpine, A. Blesch, and M. G. Tansey, "Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats," Molecular Therapy, vol. 16, no. 9, pp. 1572-1579, 2008.
174. F. E. McAlpine, J.-K. Lee, A. S. Harms et al., "Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology," Neurobiology of Disease, vol. 34, no. 1, pp. 163-177, 2009.
175. N. Badiola, C. Malagelada, N. Llecha et al., "Activation of caspase-8 by tumour necrosis factor receptor 1 is necessary for caspase-3 activation and apoptosis in oxygen-glucose deprived cultured cortical cells," Neurobiology of Disease, vol. 35, no. 3, pp. 438-447, 2009.
176. H. A. Arnett, J. Mason, M. Marino, K. Suzuki, G. K. Matsushima, and J. P.-Y. Ting, "TNFα promotes proliferation of oligodendrocyte progenitors and remyelination," Nature Neuroscience, vol. 4, no. 11, pp. 1116-1122, 2001.
177. R. Fischer, H. Wajant, R. Kontermann, K. Pfizenmaier, and O. Maier, "Astrocyte-specific activation of TNFR2 promotes oligodendrocy tematuration by secretion of leukemia inhibitory factor," Glia, vol. 62, no. 2, pp. 272-283, 2014.
178. J. R. Patel, J. L. Williams, M. M. Muccigrosso et al., "Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS," Acta Neuropathologica, vol. 124, no. 6, pp. 847-860, 2012.
179. O. Maier, R. Fischer, C. Agresti, and K. Pfizenmaier, "TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress," Biochemical and Biophysical Research Communications, vol. 440, no. 2, pp. 336-341, 2013.
180. Z. Zhou, M. C. Connell, and D. J. MacEwan, "TNFR1-induced NF-κB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells," Cellular Signalling, vol. 19, no. 6, pp. 1238-1248, 2007.
181. R. Brambilla, V. Bracchi-Ricard, W.-H. Hu et al., "Inhibition of astroglial nuclear factor κB reduces inflammation and improves functional recovery after spinal cord injury," The Journal of Experimental Medicine, vol. 202, no. 1, pp. 145-156, 2005.
182. R. Brambilla, T. Persaud, X. Hu et al., "Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation," Journal of Immunology, vol. 182, no. 5, pp. 2628-2640, 2009.
183. R. Brambilla, G. Dvoriantchikova, D. Barakat, D. Ivanov, J. R. Bethea, and V. I. Shestopalov, "Transgenic inhibition of astroglial NF-κB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis," Journal of Neuroinflammation, vol. 9, article no. 213, 2012.
184. R. G. Kilbourn, S. S. Gross, A. Jubran et al., "NG-methyl-Larginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 9, pp. 3629-3632, 1990.
185. M. Mir, L. Tolosa, V. J. Asensio, J. Lladó, and G. Olmos, "Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation," Journal of Neuroimmunology, vol. 204, no. 1-2, pp. 101-109, 2008.
186. M. Mir, V. J. Asensio, L. Tolosa et al., "Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative stress and motoneuron death in rat spinal cord embryonic explants," Neuroscience, vol. 162, no. 4, pp. 959-971, 2009.
187. R. Medeiros, R. D. S. Prediger, G. F. Passos et al., "Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein," Journal of Neuroscience, vol. 27, no. 20, pp. 5394-5404, 2007.
188. K. T. Moe, S. Aulia, F. Jiang et al., "Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor- α in human aortic smooth muscle and embryonic kidney cells," Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 231-239, 2006.
189. Q. Li, N. Y. Spencer, F. D. Oakley, G. R. Buettner, and J. F. Engelhardt, "Endosomal Nox2 facilitates redox-dependent induction of NF-kappaB by TNF-alpha," Antioxidants & Redox Signaling, vol. 11, no. 6, pp. 1249-1263, 2009.
190. P. K. Mander, A. Jekabsone, and G. C. Brown, "Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase," The Journal of Immunology, vol. 176, no. 2, pp. 1046-1052, 2006.
191. B. Yazdanpanah, K. Wiegmann, V. Tchikov et al., "Riboflavin kinase couples TNF receptor 1 to NADPH oxidase," Nature, vol. 460, no. 7259, pp. 1159-1163, 2009.
192. C. Crisafulli, M. Galuppo, and S. Cuzzocrea, "Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages," Pharmacological Research, vol. 60, no. 4, pp. 332-340, 2009.
193. R. Medeiros, C. P. Figueiredo, P. Pandolfo et al., "The role of TNF-α signaling pathway on COX-2 upregulation and cognitive decline induced by β-amyloid peptide," Behavioural Brain Research, vol. 209, no. 1, pp. 165-173, 2010.
194. G. Tezel, X. Yang, J. Yang, and M. B. Wax, "Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice," Brain Research, vol. 996, no. 2, pp. 202-212, 2004.
195. A. Kanthasamy, H. Jin, S. Mehrotra, R. Mishra, and A. Rana, "Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease," Neuro Toxicology, vol. 31, no. 5, pp. 555-561, 2010.
196. K.-B. Chen, K. Uchida, H. Nakajima et al., "Tumor necrosis factor-α antagonist reduces apoptosis of neurons and oligodendroglia in rat spinal cord injury," Spine, vol. 36, no. 17, pp. 1350-1358, 2011.
197. M. Emmanouil, E. Taoufik, V. Tseveleki et al., "Neuronal IkappaB kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system," Journal of Immunology, vol. 183, no. 12, pp. 7877-7889, 2009.
198. P. Blume-Jensen, R. Janknecht, and T. Hunter, "The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136," Current Biology, vol. 8, no. 13, pp. 779-782, 1998.
199. S. R. Datta, H. Dudek, T. Xu et al., "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery," Cell, vol. 91, no. 2, pp. 231-241, 1997.
200. J. U.-M. Wang, J.-R. Chao, W. Chen, M.-L. Kuo, J. J.-Y. Yen, and H.-F. Yang-Yen, "The antiapoptotic gene mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB," Molecular and Cellular Biology, vol. 19, no. 9, pp. 6195-6206, 1999.
201. M. H. Cardone, N. Roy, H. R. Stennicke et al., "Regulation of cell death protease caspase-9 by phosphorylation," Science, vol. 282, no. 5392, pp. 1318-1321, 1998.
202. C. Veroni, L. Gabriele, I. Canini et al., "Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways," Molecular and Cellular Neuroscience, vol. 45, no. 3, pp. 234-244, 2010.
203. O. Baud, R. F. Haynes, H. Wang et al., "Developmental upregulation of MnSOD in rat oligodendrocytes confers protection against oxidative injury," The European Journal of Neuroscience, vol. 20, no. 1, pp. 29-40, 2004.
204. J. E. Chipuk, T. Moldoveanu, F. Llambi, M. J. Parsons, and D. R. Green, "The BCL-2 family reunion," Molecular Cell, vol. 37, no. 3, pp. 299-310, 2010.
205. D. Faustman and M. Davis, "TNF receptor 2 pathway: drug target for autoimmune diseases," Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 482-493, 2010.
206. I. M. Nijholt, I. Granic, P. G. M. Luiten, and U. L. M. Eisel, "TNFR2-target for therapeutics against neurodegenerative diseases?" Advances in Experimental Medicine and Biology, vol. 691, pp. 567-573, 2011.